Morgan Stanley Syros Pharmaceuticals, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	BUY	$0.69 - $1.21 $12,724 - $22,314	18,442 Added 22.89%	99,019 $95,000
Q2 2022 Aug 15, 2022	BUY	$0.69 - $1.21 $12,724 - $22,314	18,442 Added 22.89%	99,019 $95,000
Q1 2022 Oct 27, 2022	SELL	$1.02 - $3.8 $18,810 - $70,079	-18,442 Reduced 18.62%	80,577 $95,000
Q1 2022 May 13, 2022	BUY	$1.02 - $3.8 $10,952 - $40,804	10,738 Added 15.38%	80,577 $95,000
Q4 2021 Feb 14, 2022	SELL	$3.26 - $4.66 $520,250 - $743,670	-159,586 Reduced 69.56%	69,839 $227,000
Q3 2021 Nov 15, 2021	BUY	$4.08 - $5.66 $936,054 - $1.3 Million	229,425 New	229,425 $1.03 Million

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.